Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5693312 A
Publication typeGrant
Application numberUS 08/470,143
Publication date2 Dec 1997
Filing date6 Jun 1995
Priority date26 Mar 1993
Fee statusLapsed
Also published asCA2120048A1, CA2120048C, DE4410470A1
Publication number08470143, 470143, US 5693312 A, US 5693312A, US-A-5693312, US5693312 A, US5693312A
InventorsFederico Stroppolo, Daniele Bonadeo, Luigi Vigano, Annibale Gazzaniga
Original AssigneeZambon Group S.P.A.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pharmaceutical composition having analgesic activity
US 5693312 A
Abstract
Pharmaceutical compositions having analgesic activity containing (S)-2-(6-methoxy-2-naphthyl)-propionic acid as active ingredient and arginine, useful for the preparation of pharmaceutical forms for oral route, are described,
Images(8)
Previous page
Next page
Claims(27)
What we claim is:
1. A pharmaceutical composition, consisting essentially of:
(a) (S)-2-(6-methoxy-2-naphthyl)propionic acid;
(b) arginine; and
(c) a sufficient amount of a pharmaceutically acceptable auxiliary base, such that said pharmaceutical composition, when dissolved in water, affords an aqueous solution having a pH of from 7.5 to 9.0;
wherein:
(i) said (S)-2-(6-methoxy-2-naphthyl)propionic acid and said arginine are present in relative amounts such that the molar ratio of (S)-2-(6-methoxy-2-naphthyl)propionic acid to arginine is from 1:0.8 to 1:1.5; and
(ii) said pharmaceutically acceptable auxiliary base and said (S)-2-(6-methoxy-2-naphthyl)propionic acid are present in relative amounts such that the molar ratio of pharmaceutically acceptable auxiliary base to (S)-2-(6-methoxy-2-naphthyl)propionic acid is from 0:1 to 0.7:1.
2. The pharmaceutical composition of claim 1, wherein said arginine is L-arginine.
3. The pharmaceutical composition of claim 1, wherein said molar ratio of (S)-2-(6-methoxy-2-naphthyl)propionic acid to arginine is from 1:0.8 to 1:1.2.
4. The pharmaceutical composition of claim 1, wherein said molar ratio of (S)-2-(6-methoxy-2-naphthyl)propionic acid to arginine is 1:1.1.
5. The pharmaceutical composition of claim 1, wherein said pharmaceutically acceptable auxiliary base is selected from the group consisting of sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, disodium phosphate, dipotassium phosphate, sodium phosphate(Na3 PO4), potassium phosphate (K3 PO4), sodium citrate, potassium citrate, sodium tartrate, potassium tartrate, N-methylglucamine, D-glucamine, glucosamine, and mixtures thereof.
6. The pharmaceutical composition of claim 1, wherein said pharmaceutically acceptable auxiliary base is sodium bicarbonate or potassium bicarbonate.
7. The pharmaceutical composition of claim 1, wherein said molar ratio of pharmaceutically acceptable auxiliary base to (S)-2-(6-methoxy-2-naphthyl)propionic acid is from 0.2:1 to 0.4:1.
8. The pharmaceutical composition of claim 1, wherein said (S)-2-(6-methoxy-2-naphthyl)propionic acid is present in an amount of 125 mg.
9. The pharmaceutical composition of claim 1, wherein said (S)-2-(6-methoxy-2-naphthyl)propionic acid is present in an amount of 250 mg.
10. The pharmaceutical composition of claim 1, wherein said (S)-2-(6-methoxy-2-naphthyl)propionic acid is present in an amount of 500 mg.
11. The pharmaceutical composition of claim 1, further consisting essentially of a pharmaceutically acceptable excipient.
12. A pharmaceutical composition, consisting essentially of:
(a) (S)-2-(6-methoxy-2-naphthyl)propionic acid;
(b) arginine; and
(c) a sufficient amount of a pharmaceutically acceptable auxiliary base, such that said pharmaceutical composition, when dissolved in water, affords an aqueous solution having a pH of from 7.5 to 9.0;
wherein:
(i) said (S)-2-(6-methoxy-2-naphthyl)propionic acid and said arginine are present in relative amounts such that the molar ratio of (S)-2-(6-methoxy-2-naphthyl)propionic acid to arginine is from 1:1 to 1:08; and
(ii) said pharmaceutically acceptable auxiliary base and said (S)-2-(6-methoxy-2-naphthyl)propionic acid are present in relative amounts such that the molar ratio of pharmaceutically acceptable auxiliary base to (S)-2-(6-methoxy-2-naphthyl)propionic acid is up to 0.7:1.
13. The pharmaceutical composition of claim 12, wherein said arginine is L-arginine.
14. The pharmaceutical composition of claim 12, wherein said pharmaceutically acceptable auxiliary base is selected from the group consisting of sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, disodium phosphate, dipotassium phosphate, sodium phosphate (Na3 PO4), potassium phosphate (K3 PO4), sodium citrate, potassium citrate, sodium tartrate, potassium tartrate, N-methylglucamine, D-glucamine, glucosamine, and mixtures thereof.
15. The pharmaceutical composition of claim 12, wherein said pharmaceutically acceptable auxiliary base is sodium bicarbonate or potassium bicarbonate.
16. The pharmaceutical composition of claim 12, wherein said molar ratio of pharmaceutically acceptable auxiliary base to (S)-2-(6-methoxy-2-naphthyl)propionic acid is from 0.2:1 to 0.4:1.
17. The pharmaceutical composition of claim 12, wherein said (S)-2-(6-methoxy-2-naphthyl)propionic acid is present in an amount of 125 mg.
18. The pharmaceutical composition of claim 12, wherein said (S)-2-(6-methoxy-2-naphthyl)propionic acid is present in an amount of 250 mg.
19. The pharmaceutical composition of claim 12, wherein said (S)-2-(6-methoxy-2-naphthyl)propionic acid is present in an amount of 500 mg.
20. The pharmaceutical composition of claim 12, further consisting essentially of a pharmaceutically acceptable excipient.
21. A pharmaceutical composition, consisting essentially of:
(a) (S)-2-(6-methoxy-2-naphthyl)propionic acid; and
(b) arginine; and
wherein:
(i) said (S)-2-(6-methoxy-2-naphthyl)propionic acid and said arginine are present in relative amounts such that the molar ratio of (S)-2-(6-methoxy-2-naphthyl)propionic acid to arginine is at least 1:1.5 and said arginine is present in a sufficient molar excess over said (S)-2-(6-methoxy-2-naphthyl)propionic acid such that said pharmaceutical composition, when dissolved in water, affords an aqueous solution having a pH of from 7.5 to 9.0.
22. The pharmaceutical composition of claim 21, wherein said arginine is L-arginine.
23. The pharmaceutical composition of claim 21, wherein said molar ratio of (S)-2-(6-methoxy-2-naphthyl)propionic acid and arginine is 1:1.1.
24. The pharmaceutical composition of claim 21, wherein said (S)-2-(6-methoxy-2-naphthyl)propionic acid is present in an amount of 125 mg.
25. The pharmaceutical composition of claim 21, wherein said (S)-2-(6-methoxy-2-naphthyl)propionic acid is present in an amount of 250 mg.
26. The pharmaceutical composition of claim 21, wherein said (S)-2-(6-methoxy-2-naphthyl)propionic acid is present in an amount of 500 mg.
27. The pharmaceutical composition of claim 21, further consisting essentially of a pharmaceutically acceptable excipient.
Description

This application is a continuation of application Ser. No. 08/219,309, filed on Mar. 28, 1994, now abandoned.

The present invention relates to a pharmaceutical composition with analgesic activity and, more particularly, it relates to a pharmaceutical composition containing (S)-2-(6-methoxy-2-naphthyl) propionic acid as active ingredient, useful for the preparation of pharmaceutical formulations for oral use.

(S)-2-(6-methoxy-2-naphthyl)propionic acid and its salts with pharmaceutically acceptable organic or inorganic bases have been described for the first time in U.S. Pat. No. 3,904,682 (Syntax Corporation).

Subsequently, the salts of some non-steroidal antiinflammatory drugs (NSAIDs) with basic aminoacids have been described in U.S. Pat. No. 4,279,926 (SPA-Societa Prodotti Antibiotici S.p.A.) to be particularly useful for the preparation of injectable pharmaceutical formulations because of their solubility in water giving neutral aqueous solutions.

Since several years, (S)-2-(6-methoxy-2-naphthyl)propionic acid, hereinafter indicated with the International Nonproprietary Name (INN) Naproxen, is used in therapy as free acid or as a salt, especially sodium or piperazine salt, for its analgesic, antiinflammatory and antipyretic properties (Merck Index, XI ed., No. 6337, page 1014).

Naproxen is orally administered at daily doses of 500-1500 mg. The maximum plasmatic concentration is generally between 49 and 90 μg/ml and it is reached in about two hours Verbruggen and Moll, Nonclassical oral formulations of NSAIDs, page 391--"Therapeutic Applications of NSAIDs", edited by J. P. Famaey, Harold E. Paulus, Marcel Dekker Inc., New York, (1992)!.

It is clear that the need of pharmaceutical compositions able to anticipate the onset of the pharmacological effect of non-steroidal antiinflammatory drugs is highly felt, particularly in the analgesic therapy.

U.S. Pat. No. 4,587,249 (Analgesic Associates) describes an analgesic and antiinflammatory composition containing an association of caffeine and a non-steroidal antiinflammatory drug able to increase the analgesic and antiinflammatory effect and to anticipate its onset.

Both caffeine and non-steroidal antiinflammatory drugs are commonly used in analgesic therapy.

U.S. Pat. No. 4,834,966 (Zambon S.p.A.) describes Ibuprofen water-soluble compositions containing 33-46% by weight of Ibuprofen, 34-51% by weight of L-arginine and 9-29% by weight of sodium bicarbonate which allow to obtain an increase of Ibuprofen maximum plasmatic concentration and a remarkable anticipation of the onset time of the analgesic effect.

The molar ratio between arginine and Ibuprofen must be from 1.1 to 1.5 while the weight ratio between sodium bicarbonate and Ibuprofen is from 0.25 to 0.75.

We have now surprisingly found a pharmaceutical composition containing Naproxen and arginine able to significantly anticipate the onset of the analgesic effect after opal administration.

Therefore, object of the present invention is a pharmaceutical composition useful for the preparation of pharmaceutical formulations for opal use consisting of a mixture of Naproxen and arginine in a molar ratio from 1:0.8 to 1:1.5 and of an optional pharmaceutically compatible auxiliary basic substance in a molar ratio up to 0.7 with respect to Naproxen, so that, if dissolved in water, the resultant aqueous solution has a pH value from 7.5 to 9.0. Naproxen is used in the mixture in the form of free acid.

Arginine is preferably L-arginine.

The molar ratio between Naproxen and arginine is preferably between 1:0.8 and 1:1.2, still more preferably it is 1:1.1.

Specific examples of pharmaceutically compatible auxiliary basic substances are inorganic bases such as sodium or potassium bicarbonate, sodium or potassium carbonate, disodium or dipotassium phosphate, sodium phosphate (Na3 PO4) or potassium phosphate (K3 PO4) or organic bases such as sodium or potassium citrate, sodium or potassium tartrate, N-methylglucamine, D-glucamine or glucosamine and mixtures thereof.

Exclusively for practical and economical reasons, sodium or potassium bicarbonate is preferably used.

Preferably, the molar ratio between Naproxen and the pharmaceutically compatible auxiliary basic substance, when present, is comprised from 1:0.2 to 1:0.4.

The pharmaceutical composition object of the present invention allows to obtain a significant anticipation of the onset of the analgesic effect after oral administration and it is particularly useful for the preparation of pharmaceutical formulations for oral use such as tablets, effervescent tablets, granulates, powders, syrups and solutions.

The peculiar characteristic of the composition object of the present invention is arginine.

It is worth underlining that arginine can be present also in stoichiometric default with respect to the molar amount of Naproxen. Furthermore, the pharmaceutical composition of the invention is hydrosoluble giving aqueous solutions with a pH from 7.5 to 9.0.

It is clear to the man skilled in the art that the pH value of the aqueous solution is mainly due to the presence of arginine and, consequently, when arginine is in a molar excess, the addition of the auxiliary basic substance may not be necessary.

The choice of the optional pharmaceutically compatible auxiliary basic substance has also the purpose of improving the characteristic of the finished pharmaceutical formulation.

For example, the use of an inorganic base such as sodium or potassium bicarbonate improves the rheological characteristics of the mixture making it particularly suitable for the granulation and the compression.

The preparation of the pharmaceutical compositions object of the present invention is carried out by mixing according to usual techniques.

As already underlined, the compositions object of the present invention allow to obtain a significant anticipation of the onset of the analgesic effect with respect to formulations on the market containing sodium Naproxen (example 16).

A significant anticipation of the onset of the analgesic effect due to an increase of the maximum plasmatic concentration is obtained with the compositions of the present invention also when compared to compositions containing an equivalent amount of Naproxen in the form of arginine salt (example 17).

It is worth noting that the AUC (Area Under Curve) is substantially the same in the compositions of the invention and in formulations containing sodium Naproxen present on the market or in the formulation containing only the arginine salt of Naproxen.

From a practical point of view, this means that the analgesic effect begins in advance (generally after some minutes) and lasts longer.

It is not yet clear the mechanism through which the compositions of the invention give rise to such a remarkable anticipation of the onset of the analgesic effect of Naproxen with respect to commercial formulations of sodium Naproxen.

This result does not appear to be dependent on either partial total salification of Naproxen so that the dissolution step is hastened at gastric level because it is known that the sodium salt of Naproxen is much more soluble, and consequently allows a much higher dissolution speed at gastric level, than the arginine salt A. Fini et al., Pharm. Acta Helv., 60(2), 58-62, (1985)!.

Tentatively, it could be argued that arginine has an active role at gastric level in the step of absorption of Naproxen in the form of free acid.

On the other hand, the compositions object of the present invention behave differently at gastric level in comparison with compositions containing the salt of Naproxen with arginine.

In fact, the presence of a slight excess of arginine or of small amounts of a pharmaceutically compatible auxiliary basic substance, according to the invention, allows to significantly increase the percentage of dissolved active ingredient (Naproxen) in the stomach in comparison with the gastric dissolution of the simple arginine salt (Example 18).

For the preparation of pharmaceutical formulations such as tablets, effervescent tablets, granulates, powders, syrups and solutions, further excipients suitable for the pharmaceutical use such as, for example, sweetening agents, flavoring agents, effervescent mixtures and coloring agents, can be added to the composition object of the present invention.

Preferably, the pharmaceutical formulations will contain an amount of Naproxen equal to 125, 250 or 500 mg.

The preparation of the pharmaceutical formulations is carried out according to conventional techniques of granulation, compression and dilution.

In order to better illustrate the present invention, without limiting it, the following examples are now given.

EXAMPLE 1

A mixture having the following composition

______________________________________  Naproxen      500    g  L-Arginine    416    g______________________________________

was prepared by mixing the two powders, separately sieved, in a mixer up to homogeneity.

The aqueous solution obtained by dissolving 0.916 g of the resultant mixture in 200 ml of water has pH=8.2.

EXAMPLE 2

A mixture having the following composition

______________________________________  Naproxen      500    g  L-Arginine    416    g______________________________________

was prepared by wet granulation and the granulate was dried in a static oven.

EXAMPLE 3

A mixture having the following composition

______________________________________Naproxen              500    gL-Arginine            302.5  gSodium bicarbonate    73     g______________________________________

was prepared by mixing the three powders, separately sieved, in a mixer up to homogeneity.

EXAMPLE 4

A mixture having the following composition

______________________________________Naproxen              500    gL-Arginine            302.5  gSodium bicarbonate    73     g______________________________________

was prepared by wet granulation and the granulate was dried in static oven.

EXAMPLE 5

A mixture having the following composition

______________________________________Naproxen              500    gL-Arginine            378.2  gSodium bicarbonate    36.5   g______________________________________

was prepared by mixing the three powders, separately sieved, in a mixer up to homogeneity.

EXAMPLE 6

A mixture having the following composition

______________________________________Naproxen              500    gL-Arginine            378.2  gSodium bicarbonate    36.5   g______________________________________

was prepared by wet granulation and the granulate was dried in a static oven.

EXAMPLE 7

A mixture having the following composition

______________________________________  Naproxen      500    g  L-Arginine    560    g______________________________________

was prepared by mixing the two powders, separately sieved, in a mixer up to homogeneity.

Alternatively, the mixture was granulated with water and the granulate was dried in a static oven.

EXAMPLE 8

A mixture having the following composition

______________________________________Naproxen              500    gL-Arginine            378.2  gSodium bicarbonate    54.7   g______________________________________

was prepared by wet granulation and the granulate was dried in a static oven.

EXAMPLE 9

Saccharose (1939 g), sodium saccharin (20 g), aspartame (25 g) and mint flavour (100 g) were added to a mixture prepared as described in Example 1.

The resultant mixture was shared into about 1000 sachets having the following composition (3 g in all)

______________________________________Naproxen              500    mgL-Arginine            416    mgSaccharose            1939   mgSodium saccharin      20     mgAspartame             25     mgMint flavour          100    mg______________________________________
EXAMPLE 10

Saccharose (1939 g), sodium saccharin (20 g), aspartame (25 g) and mint flavour (100 g) were added to a granulate prepared as described in Example 2.

The resultant mixture was shared into about 1000 paper-aluminum-polyethylene sachets having the following composition (3 g in all)

______________________________________Naproxen              500    mgL-Arginine            416    mgSaccharose            1939   mgSodium saccharin      20     mgAspartame             25     mgMint flavour          100    mg______________________________________

Alternatively, the mixture was shared into sachets containing 1.5 g or 0.75 g, corresponding to 250 or 125 mg of Naproxen respectively.

EXAMPLE 11

Microcrystalline cellulose (116 g), crosslinked polyvinylpyrrolidone (40 g) and magnesium stearate (8 g) were added to a granulate prepared as described in Example 2 and the resultant mixture was mixed up to homogeneity.

The mixture was compressed obtaining tablets (1.080 g) each containing 500 mg of Naproxen.

Alternatively, tablets weighing 0.540 g or 0.270 g each and containing 250 mg or 125 mg of Naproxen respectively were prepared.

EXAMPLE 12

Sorbitol (1939 g), sodium saccharin (20 g), aspartame (60 g) and apricot flavour (100 g) were added to a granulate prepared as described in Example 4.

The resultant mixture was shared into about 1000 paper-aluminum-polyethylene sachets at the rate of 3 g each.

Alternatively, the mixture was shared into sachets containing 1.5 g or 0.75 g, corresponding to 250 or 125 mg of Naproxen respectively.

EXAMPLE 13

Xylitol (900.3 g), sodium saccharin (25 g), aspartame (60 g) and anise flavour (100 g) were added to a mixture prepared as described in Example 6.

The resultant mixture was shared into about 1000 sachets having the following composition (2 g in all)

______________________________________Naproxen              500    mgL-Arginine            378.2  mgSodium bicarbonate    36.5   mgXylitol               900.3  mgSodium saccharin      25     mgAspartame             60     mgAnise flavour         100    mg______________________________________
EXAMPLE 14

Sodium bicarbonate (800 g), sodium bitartrate (900 g), aspartame (40 g) and flavour (100 g) were added to a mixture prepared as described in Example 7

The resultant mixture was compressed thus obtaining effervescent tablets (2.9 g) each containing 500 mg of Naproxen.

Alternatively, effervescent tablets weighing 1.45 g and each containing 250 mg of Naproxen were prepared.

EXAMPLE 15

Sodium bicarbonate (800 g), sodium bitartrate (900 g), saccharose (1140 g) and flavour (100 g) were added to a mixture prepared as described in Example 7.

The resultant mixture was compressed obtaining effervescent tablets (4 g) each containing 500 mg of Naproxen.

Alternatively, effervescent tablets weighing 2 g or 1 g each and containing 250 or 125 mg of Naproxen respectively were prepared.

EXAMPLE 16

Aqueous solutions of a granulate prepared as described in Example 1, containing 500 mg of Naproxen (treatment A) and of a sodium Naproxen commercial granulate, containing an equivalent amount of active ingredient (treatment B) were administered with a single dose by oral route to 12 subjects aged 32.5±4.05.

Each subject was apparently healthy, in particular as far as the renal, hepatic and hematopoietic functions were concerned.

Each subject received both preparations in two treatment sessions carried out two weeks apart, randomizing the order of administration.

During each session, basal samples of venous blood were drawn (in the morning) from each fasting subject, prior to oral administration of the preparation A or B. Further venous blood samples were also drawn 0.25, 0.50, 0.75, 1, 2, 3, 4, 8, 12 and 24 hours after treatment.

The analytical determination of Naproxen in the blood samples was carried out following the HPLC method hereinafter described.

Chromatographic conditions:

Apparatus HP 1090 L equipped with a diode array detector

HPLC column Hypersil ODS (5 μm, 100×2.1 mm) plus a precolumn Hypersil ODS (5 μm, 20×2.1 mm)

Mobile phase: Na2 HPO4 ·2H2 O 0.03M (corrected to pH 3 with H3 PO4 :CH3 OH=48:52)

Flow: 0.5 ml/min

Column temperature: 40° C.

Wavelength: 230.4 nm

Internal standard: a solution of Flurbiprofen in methanol (0.15 mg/ml)

The internal standard (0.2 ml) was added to plasma (0.1 ml). The whole was mixed and allowed to rest.

After 30 minutes, it was centrifuged at 4500 rounds per 10 minutes. The clear surnatant (10 μl) was injected into the HPLC system. Under the described operative conditions, the retention times were as follows:

Naproxen=3.8 minutes

Internal standard=8.7 minutes

The obtained results are reported in the following table 1.

                                  TABLE 1__________________________________________________________________________Mean plasma concentration of Naproxen after oral treatment with asolution of a pharmaceutical composition according to the presentinvention (treatment A) and after oral treatment with a commercialcomposition (treatment B).Administered dose: 500 mg of active ingredient.Plasma concentration of Naproxen (μg/ml)Time after treatment (hours)Treatment0.25    0.50       0.75           1  2   3  4   8  12 24__________________________________________________________________________A    52.2    58.6       69.8           61.3              58.6                  53.3                     48.4                         37.3                            29.9                               18.0B    13.0    22.0       31.1           43.5              61.8                  63.4                     56.0                         39.9                            32.4                               18.0__________________________________________________________________________

Pharmacokinetic parameters

The following parameters were calculated and evaluated. The area under curve of Naproxen plasma concentration from time "zero" to time 24 hours (AUCobs =AUCo→24h) expressed as μg×h×ml-1 was calculated following the trapezoidal rule method (Gibaldi M. and Perrier D., "Pharmacokinetics", pages 293-296, Marcel Dekker Inc., New York 1975).

The area under curve of Naproxen plasma concentration from time "zero" to "infinite" (AUCtot) was calculated by the following formula

AUCo→24h +AUC24h→ ∞

wherein ##EQU1## and Ke =elimination constant

The mean peak time expressed in hours was obtained by averaging the individual peak times.

The mean plasma concentration (Cmax) expressed as μg/ml was calculated by averaging the single peak values of the concentrations. The lag time (hours) is the delay between the drug administration and the beginning of the absorption.

The values of the above specified pharmacokinetic parameters are reported in the following table 2.

              TABLE 2______________________________________Pharmacokinetic parameters obtained after oral treatment with asolution of a pharmaceutical composition according to the invention(preparation A) and after oral treatment with a solution of a com-mercial composition (preparation B).Administered dose: 500 mg of active ingredient.Pharmacokinetic parameters            Preparation A                       Preparation B______________________________________AUCobs (μg × h × ml-1)            812        835AUCtot (μg × h × ml-1)            1192       1041Peak time (hours)            1.22       2.63Cmax (μg/ml)            75.4       70.6Lag time (hours) 0.02       0.12______________________________________

From the values reported in the table, it is evident that the compositions object of the present invention show a remarkable anticipation of the onset of the analgesic effect.

In fact, the peak time and the lag time are significantly lower than those of a commercial composition of sodium Naproxen and the maximum concentration (Cmax) is higher.

EXAMPLE 17

Aqueous solutions of a granulate prepared as described in Example 6, containing 250 mg of Naproxen, arginine and sodium bicarbonate (treatment A) and of a granulate, containing an equivalent amount of active ingredient but in the form of arginine salt and without sodium bicarbonate (treatment B) were administered with a single dose by opal route to 6 healthy adult male volunteers in fasting conditions.

The solutions were administered in both cases according to an open, balanced, randomized, cross-over design. A wash out period of 7 days was observed between the treatments.

For each treatment, a basal sample of venous blood was drawn from each fasting subject, prior to opal administration of the preparation A or B. Further venous blood samples were also drawn 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 24, 30 and 36 hours after treatment.

The analytical determination of Naproxen in the blood samples was carried out by HPLC with U.V. detection.

Chromatographic conditions:

HPLC column Hypersil ODS (5 μm, 100×2.1 mm) plus a precolumn Hypersil ODS (5 μm, 20×2.1 mm)

Mobile phase: Na2 HPO4 ·2H2 O 0.03M (corrected to pH 3 with H3 PO4 :CH3 OH=48:52)

Flow: 0.5 ml/min

Column temperature: 40° C.

Wavelength: 230.4 nm

Internal standard: a solution of Flurbiprofen in methanol (0.15 mg/ml)

The internal standard (0.2 ml) was added to plasma (0.1 ml). The whole was mixed and allowed to rest at 4° C.

After 30 minutes, it was centrifuged at 4500 rounds per 10 minutes. The clear surnatant (0.1 ml) was injected into the HPLC system. The obtained results are reported in the following table 3.

              TABLE 3______________________________________Mean plasma concentration of Naproxen after oral treatment with asolution of a pharmaceutical composition according to the presentinvention (treatment A) and after oral treatment with a compositioncontaining only Naproxen in the form of arginine salt (treatment B).Administered dose: 250 mg of active ingredient.Naproxen plasma concentration (μg/ml)Time after treatment(hours)         Treatment A                     Treatment B______________________________________0.17            20.0      19.10.33            28.5      27.70.5             30.4      29.30.75            35.2      31.21               33.6      30.61.5             32.0      29.52               30.6      29.32.5             28.5      27.93               26.5      26.74               25.1      24.28               19.8      18.712              16.6      15.024              10.8      9.0230              6.65      6.3136              3.60      4.20______________________________________

Pharmacokinetic parameters

The following parameters were calculated and evaluated. The area under curve of Naproxen plasma concentration from time "zero" to time 36 hours (AUCobs =AUCo→36h) expressed as μg×h×ml-1 was calculated following the trapezoidal rule method (Gibaldi M. and Perrier D., "Pharmacokinetics", pages 293-296, Marcel Dekker Inc., New York 1975).

The area under curve of Naproxen plasma concentration from time "zero" to "infinite" (AUCtot)) was calculated by the following formula

AUCo36h →+AUC36h →∞

wherein ##EQU2## and Ke =elimination constant

The mean peak time expressed in hours was obtained by averaging the individual peak times.

The mean plasma concentration (Cmax) expressed as μg/ml was calculated by averaging the single peak values of the concentrations. The elimination half-life (t1/2) expressed in hours.

The values of the above specified pharmacokinetic parameters are reported in the following table 4.

              TABLE 4______________________________________Pharmacokinetic parameters obtained after oral treatment with asolution of a pharmaceutical composition according to the invention(preparation A) and after oral treatment with a solution of a compo-sition containing only an equivalent amount of Naproxen in the formof arginine salt (preparation B).Administered dose: 250 mg of active ingredient.Pharmacokinetic parameters            Preparation A                       Preparation B______________________________________AUCobs (μg × h × ml-1)            570        493AUCtot  (μg × h × ml-1)            592        535Peak time (hours)            0.70       0.68Cmax  (μg/ml)            36.8       32.4t1/2(hours)      11.8       12.0______________________________________

From the values reported in the table, it is evident that a composition containing Naproxen, arginine and sodium bicarbonate in the ratio 1:1:0.2, according to the present invention, allows to obtain a maximum plasmatic concentration (Cmax) meaningfully higher than that of a composition containing only the arginine salt of Naproxen. This means that the analgesic effect of the composition of the present invention is greater and faster.

EXAMPLE 18

Aqueous solutions (100 ml) of a granulate prepared as described in Example 8, containing 200 mg of Naproxen, arginine and sodium bicarbonate (preparation A) and of a granulate, containing an equivalent amount of active ingredient but in the form of arginine salt and without sodium bicarbonate (preparation B) were treated with HCl 0.03N (30 ml) in order to simulate the acidity produced by the gastric juice.

The resultant suspensions were filtered through a Millipore filter membrane (0.8 μm).

A quantitative determination of Naproxen present in the starting suspension, in the filtered solution and in the residue on the filter was carried out according to the following procedure.

Apparatus: Hewlett-Packard liquid chromatograph (mod. 1050 and mod. 1090A) with U.V. detector at changeable wavelength. Hewlett-Packard data recorder system (mod.3359A).

Column: Hewlett-Packard RP-18, 200×4.6 nm, 5 μm.

Chromatographic conditions:

mobile phase: tetrabutylammonium hydroxide 0.005M corrected to pH 7.0 with phosphoric acid:acetonitrile=62:38

flow: 2.0 ml/minutes

wavelength: 270 nm

eluent temperature: room temperature

column temperature: 40° C.

injected volume: 10 μl

retention time: 2.2 minutes

Preparation of the standard solution: Naproxen (200 mg) was dissolved in the mobile phase up to volume (100 ml). An aliquot (5 ml) of the resultant solution was further diluted with the mobile phase up to volume (20 ml).

Preparation of the sample solution: the starting suspension and the solution obtained after filtering the starting suspension were suitably diluted with the mobile phase in order to obtain a theoretical Naproxen concentration as equal as possible to the concentration of the standard solution (about 0.5 mg/ml). The filtered residue was dissolved with the mobile phase up to a volume corresponding as much as possible to the theoretical Naproxen concentration of the standard solution.

The resulting detected amounts of Naproxen are reported in the following table 5.

              TABLE 5______________________________________Amounts of Naproxen dissolved under simulated gastric conditionsobtained from a granulate according to the invention (preparation A)and from a granulate containing an equivalent amount of activeingredient (preparation B).          Naproxen amount (%)          Preparation A                     Preparation B______________________________________Starting suspension          100        100Filtered solution          28.45      6.15Filtered residue          71.55      93.85______________________________________

From the above data it clearly results that, under conditions simulating the gastric acidity, the composition of the present invention allows the dissolution of a higher amount of active ingredient than a composition containing an equivalent amount of Naproxen in the form of arginine salt.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3904682 *21 Jun 19739 Sep 1975Syntex Corp2-(6{40 -Methoxy-2{40 -naphthyl)acetic acid
US4279926 *3 Aug 197921 Jul 1981Spa-Societa Prodotti Antibiotici S.P.A.Phenyl alkanoic acid salt of an amino acid
US4344929 *26 Jan 198117 Aug 1982Alza CorporationMethod of delivering drug with aid of effervescent activity generated in environment of use
US4587249 *22 Aug 19846 May 1986Analgesic AssociatesAnalgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4689218 *6 Nov 198625 Aug 1987Zambon S.P.A.Effervescent composition with analgesic activity
US4834966 *22 Jul 198730 May 1989Zambon S.P.A.Pharmaceutical composition with analgesic activity
US4937080 *31 Aug 198826 Jun 1990Lejus Medical AktiebolagCoating solid particles with melt of same material; controlling temperature
US5019563 *25 May 198928 May 1991Reckitt & Colman Products LimitedPharmaceutical composition
US5053396 *1 Aug 19901 Oct 1991Blass David HFor treatment of symptoms associated with excessive alcohol intake, analgesic; nicotinamide or nicotinamide adenine dinucleotide
US5055306 *20 Oct 19888 Oct 1991Aps Research LimitedSustained-release formulations
US5262179 *26 Jun 199216 Nov 1993Nicholas Kiwi Pty Ltd.Masking unpleasant taste by mixing alkali metal bicarbonate, monohydrogen phosphate or tribasic citrate
EP0398288A2 *16 May 199022 Nov 1990MEDICE Chem.-Pharm. Fabrik Pütter GmbH & Co. KGProcess for preparing optically active 2-arylalkanoic acids, in particular 2-arylpropionic acids
EP0486045A2 *15 Nov 199120 May 1992MEDICE Chem.-Pharm. Fabrik Pütter GmbH & Co. KGS(+)-Phenyl-alkanoic acids and alpha-amino acid containing complexes
EP0486046A2 *15 Nov 199120 May 1992MEDICE Chem.-Pharm. Fabrik Pütter GmbH & Co. KGS(+)-Phenyl-alkanoic acids and aminosugar containing complexes
FR2602141A1 * Title not available
Non-Patent Citations
Reference
1A. Fini et al, "Dissolution Profiles of NSAID Carboxylic Acids and Their Salts with Different Counter Ions," Pharm. Acta Helv., vol. 60, No. 2 (1985), pp. 58-62.
2 *A. Fini et al, Dissolution Profiles of NSAID Carboxylic Acids and Their Salts with Different Counter Ions, Pharm. Acta Helv., vol. 60, No. 2 (1985), pp. 58 62.
3 *Appelgren et al. U.S. 4937080 (Jun. 28, 1990).
4 *Barry et al. U.S. 5055306 (Oct. 08, 1991).
5 *Blass U.S. 5053346 (Oct. 01, 1991).
6 *Chemical Abstracts, vol. 103, No. 8, 1985, p. 336, AN 103:59148c.
7 *Gazzaniga et al. (I) U.S. 4689218 (Aug. 25, 1989).
8 *Gazzaniga et al. (II) U.S. 4834966 (May 30, 1989).
9 *Megory et al. U.S. 5262179 (Nov. 16, 1993).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US67272862 Nov 200127 Apr 2004Cumberland Pharmaceuticals Inc.Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
US7597909 *3 Oct 20036 Oct 2009Janmarie HornackCalcium, magnesium, and/or potassium compound electrolyte; water soluble acidic vitamins, bioflavonoids, minerals, trace elements, whole plant foods containing phytonutrients, and/or herbs; beverages
WO2001028538A2 *18 Oct 200026 Apr 2001Barras NormanLaxative preparation containing l-arginine
WO2003039532A1 *2 Nov 200115 May 2003Cumberland Pharmaceuticals IncPharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
WO2008144738A1 *21 May 200827 Nov 2008Glenn AbrahmsohnMethod for pain control
Classifications
U.S. Classification424/44, 514/557, 514/960, 424/717, 514/568
International ClassificationA61P25/04, A61K47/02, A61K9/16, A61K31/198, A61K9/46, A61K47/18, A61K9/00, A61K31/19, A61K31/205, A61K31/195
Cooperative ClassificationY10S514/96, A61K9/0095, A61K31/205, A61K9/1617, A61K47/02, A61K9/0007, A61K47/183, A61K31/195, A61K31/19, A61K9/1611
European ClassificationA61K31/195, A61K47/18B, A61K9/16H2, A61K9/00L6, A61K47/02, A61K9/00Z6, A61K9/16H4, A61K31/205, A61K31/19
Legal Events
DateCodeEventDescription
19 Jan 2010FPExpired due to failure to pay maintenance fee
Effective date: 20091202
2 Dec 2009LAPSLapse for failure to pay maintenance fees
8 Jun 2009REMIMaintenance fee reminder mailed
2 Aug 2007ASAssignment
Owner name: ZAMBON S.P.A., ITALY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZAMBON GROUP S.P.A.;REEL/FRAME:019640/0959
Effective date: 20070101
5 May 2005FPAYFee payment
Year of fee payment: 8
16 Apr 2001FPAYFee payment
Year of fee payment: 4
24 Feb 1998CCCertificate of correction